Focus: Sionna Therapeutics is a public biotech company focused on small-molecule therapeutics targeting cystic fibrosis, a rare genetic disease with high unmet medical need. Founded in 2019 and headquartered in Waltham, MA, the company operates as a clinical-stage biotech with a concentrated pipeline.
Profile data last refreshed 4h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Sionna Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Sionna Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Sionna Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Sionna Therapeutics (SION) Sees Slight Decline Amidst Key Support Test - Pre-Earnings Momentum - The Legal Advocate
Sionna Therapeutics (SION) Sees Slight Decline Amidst Key Support Test - Pre-Earnings Momentum The Legal Advocate
Biotech Sionna Therapeutics at Jefferies and Goldman Sachs in June - Stock Titan
Biotech Sionna Therapeutics at Jefferies and Goldman Sachs in June Stock Titan
Stifel Nicolaus Sticks to Their Buy Rating for Sionna Therapeutics, Inc. (SION) - The Globe and Mail
Stifel Nicolaus Sticks to Their Buy Rating for Sionna Therapeutics, Inc. (SION) The Globe and Mail
Number of shareholders of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
Number of shareholders of Sionna Therapeutics, Inc. – NASDAQ:SION TradingView
Wedbush Initiates Coverage of Sionna Therapeutics (SION) - Insider Monkey
Wedbush Initiates Coverage of Sionna Therapeutics (SION) Insider Monkey
Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference - GlobeNewswire
Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference GlobeNewswire
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Study Design Considerations for the Evaluation of Pancreatic Enzyme Replacement Therapy (PERT) Products in People with Cystic Fibrosis: An Update.
Inhibition of dimeric SARS-CoV-2 Mpro displays positive cooperativity and a mixture of covalent and non-covalent binding.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo